Pacira BioSciences (PCRX) Income from Continuing Operations (2010 - 2026)

Pacira BioSciences' Income from Continuing Operations history runs 17 years deep, the most recent figure standing at 2916000.0 for Q1 2026.

• On a quarterly basis, Income from Continuing Operations fell 39.4% year-over-year to 2916000.0 in Q1 2026; TTM through Mar 2026 was 5138000.0, a 104.95% increase from a year earlier, with the FY2025 full-year figure at 7034000.0, up 107.07% from the prior year.
• Income from Continuing Operations advanced to 2916000.0 in Q1 2026 per PCRX's latest filing, from 1637000.0 in the prior quarter.
• Across five years, Income from Continuing Operations topped out at 25763000.0 in Q2 2023 and bottomed at 143466000.0 in Q3 2024.
• The 5-year median for Income from Continuing Operations is 5432000.0 (2025), against an average of 1867411.76.
• Across the five-year window, Income from Continuing Operations surged 1666.81% in 2023 and slumped 1421.29% in 2024, its largest moves.
• Year by year, Income from Continuing Operations stood at 10102000.0 in 2022, then soared by 346.19% to 24870000.0 in 2023, then slumped by 35.5% to 16041000.0 in 2024, then plunged by 89.79% to 1637000.0 in 2025, then soared by 78.13% to 2916000.0 in 2026.
• Per Business Quant, the three latest PCRX Income from Continuing Operations figures stand at 2916000.0 (Q1 2026), 1637000.0 (Q4 2025), and 5432000.0 (Q3 2025).